|1||Focus on ASCVD Risk Reduction: 4 Statin Benefit Groups|
|2||A New Perspective on LDL-C and/or Non–HDL-C Treatment Goals|
|3||Global Risk Assessment for Primary Prevention|
|5||Role of Biomarkers and Noninvasive Tests|
|6||Future Updates to the Blood Cholesterol Guideline|
ASCVD indicates atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and RCT, randomized controlled trial.
↵∗ See Appendix 5, for an expanded discussion of what’s new in the guideline.